Professor Shankar Siva is passionate about embracing a career as a clinician-researcher in order to improve outcomes for patients with cancer. He leads the Stereotactic Ablative Body Radiotherapy (SABR) program at Peter Mac and published the first original research on SABR in Australia. He is a leading authority in novel applications of SABR, particularly in oligometastatic disease and combinations with immunotherapy.

Prof Siva is the current recipient of the prestigious Cancer Council Victoria Colebatch Fellowship. He is an internationally recognised expert in lung and genitourinary (kidney and prostate) cancers. His personal achievements include over 250 peer-reviewed manuscript publications and podium presentations at over 120 national and international scientific meetings. He completed his PhD investigating high-tech radiation delivery and radiation biology in the context of lung cancers. He has received over 20 awards for research.   

Internationally, he serves on the Board of Directors of the Radiosurgery Society (RSS), the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) committee and the American Society of Radiation Oncology (ASTRO) Science Council. At an Australasian level, he is Chair of the TransTasman Radiation Oncology (TROG) Genitourinary Group, part of the scientific advisory of the Thoracic Oncology Group of Australasia (TOGA) and is co-founder of the Stereotactic Interest Group of Australasia (SIGA) amongst other leadership roles. He is a dedicated clinical trialist, having designed and chaired 15 investigator-initiated clinical trials in the context of lung, kidney, prostate and spinal malignancies.  His current research focuses on translating insights from the correlative specimens in his clinical trials into prognostic, predictive and actionable biomarkers.